Adjunctive Use of VGH4 for Moderate-to-Severe Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Trial
= 0.023). In conclusion, VGH4 was generally well tolerated in this short-term pilot trial, with no serious adverse events, and showed preliminary signals of possible benefits in patient-reported outcomes as an adjunct therapy. These exploratory findings warrant confirmation in larger, adequately powered trials.
Authors
- Shinn‐Jang Hwang (ORCID: https://orcid.org/0000-0003-3217-6193)
- Cheng-Hung Tsai (ORCID: https://orcid.org/0000-0002-9331-8725)
- Yen‐Ying Kung (ORCID: https://orcid.org/0000-0002-7371-734X)
- F H Chen
- Ta‐Peng Wu (ORCID: https://orcid.org/0000-0003-0390-6329)
- Ying-Ju Liao
- C C Chang
- Chih-Chiang Chen
- Yun-Ting Chang
- Chou-Cheng Lai
Institutions
- National Yang Ming Chiao Tung University (TW)
- Taipei Veterans General Hospital (TW)
- Chang Bing Show Chwan Memorial Hospital (TW)
- National Yang Ming Chiao Tung University (TW)
- National Taipei University (TW)
Publication Details
- Journal
- Life
- Published
- 2026-04-16
- DOI
- https://doi.org/10.3390/life16040680
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Taipei Veterans General Hospital